142 related articles for article (PubMed ID: 11002816)
1. Effects of vehicles and prodrug properties and their interactions on the delivery of 6-mercaptopurine through skin: bisacyloxymethyl-6-mercaptopurine prodrugs.
Waranis RP; Sloan KB
J Pharm Sci; 1987 Aug; 76(8):587-95. PubMed ID: 11002816
[TBL] [Abstract][Full Text] [Related]
2. Effects of vehicles and prodrug properties and their interactions on the delivery of 6-mercaptopurine through skin: S6-acyloxymethyl-6-mercaptopurine prodrugs.
Waranis RP; Sloan KB
J Pharm Sci; 1988 Mar; 77(3):210-5. PubMed ID: 3373424
[TBL] [Abstract][Full Text] [Related]
3. Effect of aminomethyl (N-Mannich base) derivatization on the ability of S6-acetyloxymethyl-6-mercaptopurine prodrug to deliver 6-mercaptopurine through hairless mouse skin.
Saab AN; Sloan KB; Beall HD; Villaneuva R
J Pharm Sci; 1990 Dec; 79(12):1099-104. PubMed ID: 2079657
[TBL] [Abstract][Full Text] [Related]
4. Alkylation of 6-mercaptopurine (6-MP) with N-alkyl-N-alkoxycarbonylaminomethyl chlorides: S6-(N-alkyl-N-alkoxycarbonyl)aminomethyl-6-MP prodrug structure effect on the dermal delivery of 6-MP.
Siver KG; Sloan KB
J Pharm Sci; 1990 Jan; 79(1):66-73. PubMed ID: 2313580
[TBL] [Abstract][Full Text] [Related]
5. Topical delivery of 5-fluorouracil and 6-mercaptopurine by their alkylcarbonyloxymethyl prodrugs from water: vehicle effects on design of prodrugs.
Sloan KB; Wasdo S; Ezike-Mkparu U; Murray T; Nickels D; Singh S; Shanks T; Tovar J; Ulmer K; Waranis R
Pharm Res; 2003 Apr; 20(4):639-45. PubMed ID: 12739773
[TBL] [Abstract][Full Text] [Related]
6. Correlation of aqueous and lipid solubilities with flux for prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine: A Potts-Guy approach.
Roberts WJ; Sloan KB
J Pharm Sci; 1999 May; 88(5):515-22. PubMed ID: 10229642
[TBL] [Abstract][Full Text] [Related]
7. Topical delivery of a model phenolic drug: alkyloxycarbonyl prodrugs of acetaminophen.
Wasdo SC; Sloan KB
Pharm Res; 2004 Jun; 21(6):940-6. PubMed ID: 15212157
[TBL] [Abstract][Full Text] [Related]
8. Use of solubility parameters of drug and vehicle to predict flux through skin.
Sloan KB; Koch SA; Siver KG; Flowers FP
J Invest Dermatol; 1986 Aug; 87(2):244-52. PubMed ID: 3734472
[TBL] [Abstract][Full Text] [Related]
9. The effect of vehicle on the diffusion of salicylic acid through hairless mouse skin.
Sloan KB; Siver KG; Koch SA
J Pharm Sci; 1986 Aug; 75(8):744-9. PubMed ID: 3772744
[TBL] [Abstract][Full Text] [Related]
10. 1-Alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU): synthesis, physicochemical properties, and topical delivery of 5-FU.
Taylor HE; Sloan KB
J Pharm Sci; 1998 Jan; 87(1):15-20. PubMed ID: 9452962
[TBL] [Abstract][Full Text] [Related]
11. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine with a series/parallel model.
Roberts WJ; Sloan KB
J Pharm Sci; 2000 Nov; 89(11):1415-31. PubMed ID: 11015687
[TBL] [Abstract][Full Text] [Related]
12. Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia.
Qiu J; Cheng R; Zhang J; Sun H; Deng C; Meng F; Zhong Z
Biomacromolecules; 2017 Oct; 18(10):3207-3214. PubMed ID: 28835099
[TBL] [Abstract][Full Text] [Related]
13. Topical delivery of 5-fluorouracil (5-Fu) by 3-alkylcarbonyl-5-Fu prodrugs.
Beall HD; Sloan KB
Int J Pharm; 2001 Apr; 217(1-2):127-37. PubMed ID: 11292549
[TBL] [Abstract][Full Text] [Related]
14. Topical delivery of 5-fluorouracil (5-FU) by 1,3-bisalkylcarbonyl-5-FU prodrugs.
Beall HD; Sloan KB
Int J Pharm; 2002 Jan; 231(1):43-9. PubMed ID: 11719012
[TBL] [Abstract][Full Text] [Related]
15. N-Mannich-base prodrugs of 5-iodo-2'-deoxycytidine as topical delivery enhancers.
Koch SA; Sloan KB
Pharm Res; 1987 Aug; 4(4):317-20. PubMed ID: 3508538
[TBL] [Abstract][Full Text] [Related]
16. Transdermal prodrug concepts: permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles.
Imoto H; Zhou Z; Stinchcomb AL; Flynn GL
Biol Pharm Bull; 1996 Feb; 19(2):263-7. PubMed ID: 8850319
[TBL] [Abstract][Full Text] [Related]
17. Designing for topical delivery: prodrugs can make the difference.
Sloan KB; Wasdo S
Med Res Rev; 2003 Nov; 23(6):763-93. PubMed ID: 12939791
[TBL] [Abstract][Full Text] [Related]
18. PEG prodrugs of 6-mercaptopurine for parenteral administration using benzyl elimination of thiols.
Choe YH; Greenwald RB; Conover CD; Zhao H; Longley CB; Guan S; Zhao Q; Xia J
Oncol Res; 2004; 14(9):455-68. PubMed ID: 15490977
[TBL] [Abstract][Full Text] [Related]
19. Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs.
Roberts WJ; Sloan KB
J Pharm Sci; 2003 May; 92(5):1028-36. PubMed ID: 12712422
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone.
Pillai O; Hamad MO; Crooks PA; Stinchcomb AL
Pharm Res; 2004 Jul; 21(7):1146-52. PubMed ID: 15290853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
